A calculator that corrects the QT interval for heart rate extremes.
Consuming caffeine regularly does not lead to extra heartbeats, according to a new study by researchers at UC San Francisco published in the Journal of the American Heart Association.
Stroke risk appears to more than double in the first week following a shingles diagnosis, with myocardial infarction (MI) risk also climbing, though not by quite as much, according to research published online in PLOS Medicine.
A Food and Drug Administration advisory panel has ruled 10 to 5 against allowing Merck claim their drug Vytorin (ezetimibe, simvastatin tablets) reduces the risk of heart attacks and strokes in patients with acute coronary syndromes.
Kitov Pharmaceuticals announced that the Phase 3 study for KIT-302 successfully met its primary efficacy endpoint. KIT-302 was more efficacious at reducing hypertension than amlodipine besylate.
Vagus nerve stimulation (VNS) paired with rehabilitation appears to be feasible and safe for patients after ischemic stroke, according to a study published online in Stroke.
Nitrates don't improve quality of life or everyday activity levels as intended in patients with heart failure, according to research published in the December 10 issue of the New England Journal of Medicine.
Small gallstones could be the cause of idiopathic pancreatitis in up to 10-20% of cases, a new study from the University of Eastern Finland has found
For patients with septic shock undergoing resuscitation, 28- and 90-day mortality is not significantly different with high- or low-target arterial pressure.
Risk of cardiac events is increased by exposure from breast radiotherapy, though contemporary techniques, including lower radiation doses and prone positioning, have helped lower these risks.
Actelion announced that the FDA has approved Opsumit (macitentan) tablets for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.
For patients in septic shock, the use of esmolol is linked to reductions in heart rates to target levels compared to the use of standard care.
Bayer HealthCare announced that the FDA has approved Adempas (riociguat) tablets, a first-in-class drug, for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension.
The FDA has granted Orphan Drug Designation to riociguat (Bayer HealthCare), proposed trade name Adempas, for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
The FDA approved labeling revisions for the Sapien Transcatheter Heart Valve (THV), expanding its availability to patients who have inoperable aortic valve stenosis.
Though many experience excitement, fun, and camaraderie while watching the big event, Super Bowl Sunday has a darker side. It is associated with higher rates of alcohol-related accidents and increased risk of cardiovascular deaths.
United Therapeutics announced that the FDA has accepted for review its resubmission of a New Drug Application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension.
Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.
For patients with acute ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) in non-infarct coronary arteries with major stenoses (preventive PCI) is associated with reduced subsequent cardiovascular risk.
A variant of a gene associated with glutamic acid metabolism is linked to an increased risk of coronary heart disease in patients with type 2 diabetes.
The subcutaneous implantable cardioverter-defibrillator (S-ICD System) is both safe and effective for the treatment of life-threatening ventricular arrhythmias.
Both early physician follow-up and continuity of physician care following an initial hospital diagnosis of heart failure improve patient outcomes.